Mental retardation in Down syndrome (DS) appears to be related to severe neurogenesis impairment during critical phases of brain development. Recent lines of evidence in the cerebellum of a mouse model for DS (the Ts65Dn mouse) have shown a defective responsiveness to Sonic Hedgehog (Shh), a potent mitogen that controls cell division during brain development, suggesting involvement of the Shh pathway in the neurogenesis defects of DS. Based on these premises, we sought to identify the molecular mechanisms underlying derangement of the Shh pathway in neural precursor cells (NPCs) from Ts65Dn mice. By using an in vitro model of NPCs obtained from the subventricular zone and hippocampus, we found that trisomic NPCs had an increased expression of the Shh receptor Patched1 (Ptch1), a membrane protein that suppresses the action of a second receptor, Smoothened (Smo), thereby maintaining the pathway in a repressed state. Partial silencing of Ptch1 expression in trisomic NPCs restored cell proliferation, indicating that proliferation impairment was due to Ptch1 overexpression. The overexpression of Ptch1 in trisomic NPCs resulted from increased levels of AICD [a transcription-promoting fragment of amyloid precursor protein (APP)] and increased AICD binding to the Ptch1 promoter. Our data provide novel evidence that Ptch1 overexpression underlies derangement of the Shh pathway in trisomic NPCs with consequent proliferation impairment. The demonstration that Ptch1 overexpression in trisomic NPCs is due to an APP fragment provides a link between this trisomic gene and the defective neuronal production that characterizes the DS brain.
INTRODUCTION
Down syndrome (DS) is caused by trisomy of all or part of human chromosome 21 (HSA21) and is one of the most common genetic causes of cognitive impairment and congenital abnormalities. Although most systems are affected to some degree in DS, impaired cognitive function is the most debilitating and important problem of this pathology.
The major determinant of mental retardation is considered to be the characteristically decreased brain size of individuals with DS. The hypocellularity observed in the primary visual cortex, primary somatosensory cortex, primary motor cortex, primary auditory cortex and superior temporal gyrus of individuals with DS has lead to the hypothesis that mitotic deficits characterize the DS brain (1, 2) . Consistently, recent evidence has shown a severe impairment of cellular proliferation in the ventricular germinal matrix, various structures of the hippocampal regions and cerebellum of human fetuses with DS (3 -5) , suggesting that proliferation impairment is a key factor underlying developmental neuropathology in DS individuals.
Different mouse models have been used to understand the etiology of the DS phenotype and to correlate the genetic and phenotypic changes caused by trisomy: Ts16 (6), Ts65Dn (7) and Ts1Cje (8) . These mice are trisomic for all (Ts16) or segments (Ts65Dn, Ts1Cje) of mouse chromosome 16 (Mmu16), highly homologous to the long arm of HSA21 (9) . The Ts65Dn mouse, one of the animal models most comparable to DS, both in terms of triplicated genes and phenotype (10) , exhibits small body size, alterations in the † These authors contributed equally to the work. * To whom correspondence should be addressed at: Department of Human and General Physiology, Piazza di Porta San Donato 2, I-40126 Bologna (BO), Italy. Tel: +39 0512091726; Fax: +39 0512091737; Email: elisabetta.ciani@unibo.it craniofacial skeleton and cognitive impairment (10) (11) (12) (13) . Recent evidence obtained in the Ts65Dn mouse clearly demonstrates that neurogenesis is severely impaired in the embryonic subventricular zone (SVZ) and hippocampus (14) and in the hippocampus and cerebellum of neonate mice (3, 15, 16) . This evidence validates the use of mice models to get insight into the mechanisms underlying proliferation impairment in DS.
It has recently been shown that the reduced proliferation of cerebellar granule cell precursors from Ts65Dn mice is related to an attenuated response to Sonic Hedgehog (Shh) (17) , a potent mitogen that controls cell division during brain development (18) . The Shh pathway acts on gene expression through the activity of the Gli transcription factor family that includes Gli1, Gli2 and Gli3 (19) . In the absence of Shh, its transmembrane receptor Patched1 (Ptch1) inhibits, by default, the transmembrane protein G-coupled receptor Smoothened (Smo). The Ptch1-dependent regulation of Smo activity plays a central role in mediating Shh-signaling. Increased levels of Ptch1 suppress Smo activity and prevent transcription of Gli1, indicating that over-expressed Ptch1 inhibits the Shh signaling (20, 21) . In agreement with the inhibitory role of Ptch1 in the regulation of cell proliferation, mutations in PTCH1 cause an aberrant increase in cell proliferation in a variety of tumors (22) .
The wide brain expression of the Shh pathway (18, 23) suggests that it may exert a widespread role in the regulation of neural precursor proliferation in the different brain neurogenic zones. If so, a generalized attenuation of the response to Shh might account for the widespread neurogenesis impairment that characterized the trisomic brain. Despite the recent demonstration of an attenuated mitogenic response to Shh in trisomic cerebellar granule cell precursors (17) , the molecular mechanisms underlying the impairment of this pathway are completely unknown. Although in vivo models reflect in a more realistic fashion the environment of the diseased brain, in view of the complexity of the mechanisms underlying neurological diseases, simplified in vitro approaches are often essential tools to better dissect the molecular mechanisms that take part in the pathology. In the current study, we have taken advantage of cultures of neural precursor cells (NPCs) from the SVZ and hippocampus of Ts65Dn mice (i) to establish whether NPCs from these regions exhibit a defective response to Shh similarly to cerebellar granule cell precursors and (ii) to dissect the molecular mechanisms that underlie the deregulation of the Shh pathway and, consequently, the proliferation impairment in the trisomic condition.
RESULTS

Neuronal precursor cultures from Ts65Dn mice exhibit the same neurogenesis impairment as the in vivo condition
As a first step, we attempted to establish whether neuronal precursors (NPCs) in culture exhibit proliferation/differentiation defects similar to those observed in vivo. We examined proliferation in cultures of NPCs from the SVZ, a region characterized by a severely impaired proliferation in Ts65Dn mice. Typical neurospheres appeared in cultures from both euploid and Ts65Dn mice (Fig. 1A) . The growth kinetics of NPCs from the SVZ was monitored over time. While at day 1 in vitro (DIV1) there was no difference in the morphology and number of neurospheres of Ts65Dn and euploid mice; the diameter of trisomic neurospheres was significantly smaller than that of the euploid counterpart starting from DIV3 ( Fig. 1A and B) , suggesting defective proliferation. In agreement with this finding, trisomic neurospheres exhibited a reduced BrdU incorporation rate versus the control counterpart (225%; Fig. 1C) . Similar results were obtained in neurospheres from the hippocampus of trisomic mice (230%; Supplementary Material, Fig. S1A) . No difference in apoptotic cell death was observed between control and trisomic neurospheres derived from both the SVZ and hippocampus, as estimated by cleaved caspase-3 immunostaining and pyknotic appearance of the nuclei of dying cells (data not shown). This indicates that the reduced growth and number of BrdU-positive cells observed in trisomic neurospheres were not attributable to an increased cell death.
To establish whether the reduced proliferation of trisomic NPCs was due to an increase in the cell cycle length and/or a precocious exit from the cell cycle, we evaluated the cell cycle and the size of the pool of proliferating cells (growth fraction, GF). Total cell cycle length (T C ), S-phase length (T S ) and GF were estimated by BrdU-cumulative labeling (24) . According to this protocol, successive cohorts of cells entering the S-phase are labeled with BrdU at consecutive time intervals, in order to label all proliferating cells (GF) (see Materials and Methods and Supplementary Material, Fig. S2 ). Cell cycle analysis revealed that in control neurospheres, the cell cycle length was 29.56 h. In contrast, in Ts65Dn mice, the cell cycle length was 59.02 h, which corresponds to a difference of +100% (Table 1 ). The length of the S-phase showed a small but significant increase in trisomic versus control neurospheres (Table 1) . Trisomic neurospheres had a GF similar to the euploid counterpart (Table 1) , indicating no difference in the relative size of the population of proliferating NPCs. To evaluate the length of the G 2 -and M-phases of the cell cycle, we used immunocytochemistry for phosphorylated-(Ser10)-histone-H3 (pHH3), a marker that allows discrimination of cells in either the G 2 -or M-phases, based on its nuclear pattern (25) . We found that trisomic neurospheres had a larger percentage of NPCs in G 2 and a similar percentage of cells in the M-phase compared with controls (Fig. 1E) . Evaluation of the length of the G 2 -and M-phases (see Materials and Methods) indicated a notable elongation (+159%) of the G 2 -phase in trisomic neurospheres compared with controls, while the length of the M-phase was unchanged (Table 1 ). There are no specific markers for the G 1 -phase of the cell cycle. Thus, we estimated its length by subtracting from the total cell cycle length the summed length of the remaining phases (S, G 2 , M). We found that in trisomic neurospheres, the duration of the G 1 -phase was significantly larger (+112%) than controls (Table 1) .
To determine whether NPCs from Ts65Dn mice have defective neuronal differentiation, we compared the number of neurons and astrocytes produced by trisomic versus euploid neurospheres. After 7 days in culture conditions that favor differentiation (26) , we found that the number of neurons These results indicate that cultures of trisomic NPCs are a suitable model to study the mechanisms underlying neurogenesis impairment in DS because they exhibit a reduced proliferation rate, elongation of the cell cycle and impaired acquisition of a neuronal phenotype, similarly to the in vivo condition (3, 14, 16, 27) .
Deranged expression of Shh pathway genes in neural precursors from Ts65Dn mice
It has recently been shown that the reduced proliferation of cerebellar granule cell precursors from Ts65Dn mice is related to an attenuated response to Shh (17) , suggesting an alteration in the molecular cascade of this pathway in DS.
We first performed a gene expression study, by quantitative reverse transcriptase polymerase chain reaction (RT-qPCR), to establish whether genes known to be involved in the Shh pathway exhibited an altered expression in trisomic NPCs. * P , 0.05, * * P , 0.01 (two-tailed t-test).
We found that the Gli family members Gli1, Gli2 and Gli3, which are transcription factors functioning as Shh effectors, showed a significant down-regulation (242, 246 and 260%, respectively) in trisomic neurospheres ( Fig. 2A) .
Looking at the expression of Gli target genes, we found that MycN and Bmi1 were greatly down-regulated (270 and 240%, respectively) in trisomic neurospheres (Fig. 2B) . Additionally, the expression of FoxM1, an indirect Gli target that promotes cell cycle progression at the G 2 /M-phase transition, was also down-regulated (Fig. 2B ). These observations clearly indicate derangement of the Shh pathway in NPCs from Ts65Dn mice. We next examined the expression of the membraneassociated receptors Smo and Ptch1 and the Shh ligand in euploid and trisomic neurospheres. Whereas no significant differences were observed in the expression of Shh and Smo, we found a notable up-regulation of Ptch1 in trisomic neurospheres (Fig. 2C) . Western blot and immunocytochemistry analyses showed a significantly higher expression of Ptch1 in trisomic neurospheres also at the protein level ( Fig. 2D and E) . Similar results were obtained in trisomic neurospheres derived from the hippocampus (Supplementary Material, Fig. S1B ), suggesting that an increased expression of Ptch1 may be the common molecular denominator of the Shh pathway derangement in trisomic NPCs.
Neural precursors from Ts65Dn mice do not respond to Shh
We next tested the response of NPCs from the SVZ to the Shh. Administration of Shh for 72 h induced a proliferation increase in neurospheres from control mice, but no increase in neurospheres from Ts65Dn mice (Fig. 3A) , indicating that trisomic NPCs from the SVZ are not responsive to Shh similarly to cerebellar granule cell precursors. In control neurospheres, treatment with Shh in the presence of cyclopamine, an antagonist of Smo, prevented the proliferation increase induced by Shh and, additionally, caused a decrease (220%) in cell proliferation compared with the untreated condition (Fig. 3A) . This suggested a basal activation state of the Shh pathway, probably due to paracrine production of Shh, as previously reported (28) . In contrast, co-treatment with Shh and cyclopamine had no effect on cell proliferation in trisomic neurospheres.
SAG is an agonist for Smo that relieves the inhibitory effect of Ptch1 on Smo (29) . Incubation of neurospheres with SAG enhanced cell proliferation in euploid (+23%) and trisomic (+56%) NPCs (Fig. 3A) . The latter finding clearly indicates that the Shh pathway downstream to Smo is functional in trisomic NPCs, which suggests that its impairment is upstream to Smo. As expected, co-exposure of cells to SAG and cyclopamine prevented the proliferation increase induced by SAG alone in both euploid and Ts65Dn neurospheres (Fig. 3A) . To obtain further evidence that the Shh pathway is defective in trisomic NPCs upstream to Smo, we examined Gli1, the expression of which is dependent on Shh pathway activation. While both Shh and SAG treatments significantly increased Gli1 expression in control neurospheres, in trisomic neurospheres SAG but not Shh treatment increased Gli1 expression (Fig. 3B ). These data suggest that NPCs from Ts65Dn mice are unable to respond to Shh due to up-regulation of Ptch1, which by inhibiting Smo, makes the Shh pathway functionally inactive.
Silencing of Ptch1 expression restores proliferation in neural precursors from Ts65Dn mice
To demonstrate that Ptch1 up-regulation underlies the impaired proliferation of NPCs from Ts65Dn mice, we reduced its expression by using an antisense oligonucleotide (AS) directed against Ptch1. AS treatment reduced Ptch1 expression in both euploid and trisomic neurospheres (260 and 240%, respectively) and, in trisomic neurospheres, Ptch1 expression became similar to that of the untreated euploid counterpart (Fig. 4A) . Concomitantly with the reduction in Ptch1 expression, there was an increase in cell proliferation in both euploid and trisomic neurospheres (+20% and +39%, respectively) ( Fig. 4B) .
Comparison of AS-treated trisomic neurospheres with untreated euploid neurospheres showed no proliferation differences ( Fig. 4B ), indicating that inhibition of Ptch1 expression had completely restored cell proliferation in trisomic NPCs. Treatment with a sense oligonucleotide, as a negative control, had no effect on Ptch1 expression and cell proliferation (data not shown). We next examined whether inhibition of Ptch1 expression made trisomic NPCs responsive to Shh. After treatment with AS, trisomic neurospheres became responsive to Shh and underwent a proliferation increase similarly to the euploid counterpart ( Ptch1 promoter is highly acetylated in neural precursors from Ts65Dn mice
There is evidence that the methylation and histone acetylation of the PTCH1 promoter significantly affect PTCH1 gene expression in disease conditions (30) (31) (32) . These epigenetic mechanisms have an important regulatory role in gene expression and act by inhibiting and favoring gene transcription, respectively (33) . To determine whether DNA methylation and/or histone acetylation can regulate the activity of the Ptch1 promoter in NPCs, we treated neurospheres with either 5-Aza-2 ′ -Deoxycytidine (AZA), an inhibitor of DNA methyltransferase or Trichostatin A (TSA), an inhibitor of histone deacetylase. While AZA treatment induced a small increase (2 -3-folds) in Ptch1 expression, TSA treatment highly increased (20 -22-folds) Ptch1 expression in both control and trisomic neurospheres (Fig. 5A ). This suggests that DNA methylation of the Ptch1 promoter is not a major determinant of Ptch1 regulation, while histone acetylation appears to be an important epigenetic mechanism that regulates Ptch1 expression in NPCs.
We next sought to establish whether trisomic neurospheres exhibited a different Ptch1 promoter methylation and/or acetylation status versus euploid neurospheres. To this purpose, we employed methylcytosine immunoprecipitation (mCIP) and acetyl-histone H3 immunoprecipitation [chromatin immunoprecipitation (ChIP)] assays. In the promoter region of Ptch1 (A) LI, defined as percentage of BrdU-positive cells over total cell number, was determined for neurospheres from euploid (n ¼ 3) and Ts65Dn (n ¼ 3) mice. Neurospheres were treated with Shh (3 mg/ml), cyclopamine (Cyc; 10 mg/ml), SAG (250 nM), Shh plus cyclopamine or SAG plus cyclopamine for 72 h starting from DIV1. (B) Quantification by RT -qPCR of Gli1 expression in neurospheres treated with Shh (3 mg/ml) or SAG (250 nM) for 24 h starting at DIV4 (three Ts65Dn and three euploid mice). Data are given as percentage of the euploid untreated condition. The scheme on the right shows that Shh drives the Shh pathway by removing the inhibition exerted by Ptch1 on Smo, and the negative and positive effect exerted by Cyc and SAG, respectively, on Smo. Values represent mean + SE. The asterisk indicates a significant difference in euploid and trisomic neurospheres versus euploid untreated neurospheres. The # indicates a significant difference of trisomic treated neurospheres versus trisomic untreated neurospheres.
* P , 0.05; * * P , 0.01; * * * P , 0.001 (Bonferroni's test after ANOVA).
close to the start site, there are two CpG islands ( Figure 5B (upper histograms). It can be noted that, unlike The asterisks indicate a significant difference of euploid and trisomic neurospheres versus euploid untreated neurospheres. * * P , 0.01, * * * P , 0.001 (Bonferroni's test after ANOVA). ′ -deoxycytidine (AZA, 5 mM) or TSA (150 nM) for 72 h after DIV1. Data, given as percentage of the euploid untreated condition, are expressed as mean + SE. The asterisks indicate a significant difference between euploid and trisomic neurospheres versus euploid untreated neurospheres. * * P , 0.01, * * * P , 0.001 (Bonferroni's test after ANOVA). (B) The mCIP assay (upper panels) was performed with an antimethylcytosine antibody and primers targeting amplicons a-e in neurospheres at DIV4 from trisomic (n ¼ 4) and euploid (n ¼ 4) mice. Fold enrichment of the Ptch1 gene promoter by anti-methylcytosine antibody was calculated by dividing the PCR product from amplicons b, c or e by the PCR product from amplicons a and d that represent non-CpG control regions. The ChIP assay (middle panels) was performed using an anti-Acetyl-Histone H3 and the same primers used for the mCIP. Fold enrichment of a given DNA region immunoprecipitated with the anti-Acetyl-Histone H3 antibody was calculated as the ratio between the enrichment obtained with the specific antibody compared with pre-immune serum. Values represent mean + SE.
* P , 0.05, * * P , 0.01, * * * P , 0.001 (two-tailed t-test). The lower panel shows a schematic representation of the mouse Ptch1 gene promoter. The diagram includes: transcription start site (black arrow); target regions of PCR primers for quantitative ChIP assay (amplicons a-e: gray boxes); CpG-rich region and CpG islands (black boxes).
the CpG-rich region, the CpG islands of the Ptch1 promoter were unmethylated, both in control and trisomic NPCs. In the CpG-rich region of trisomic NPCs, the methylation status was slightly, though not significantly, higher than the euploid counterpart (Fig. 5B: b) . On the contrary, we found that the histone H3 acetylation was stronger in all these regions (a-e) in trisomic versus euploid NPCs (Fig. 5B) . Table S1 ), suggesting that the increased acetylation in trisomic neurospheres is peculiar for the Ptch1 promoter.
Triplicated amyloid precursor protein increases Ptch1 expression through AICD
The gene coding for the amyloid precursor protein (APP) is among those present in trisomic dosage in DS and its expression has been found to be significantly increased in the brain of Ts65Dn mice (35) . It has been recently shown that the APP intracellular domain (AICD), which is generated from the APP protein through sequential proteolysis by b-and g-secretases, up-regulates PTCH1 expression in neuroblastoma cells (36) . AICD has been reported to form a complex with Fe65 and the histone acetyltransferase Tip60 and cause transcriptional activation by increasing the acetylation status of the chromatin (37, 38) .
Quantification of the APP gene in trisomic NPCs showed that its expression was very close to the theoretical 1.5-fold increase expected from the presence of one extra copy of APP (Fig. 6A) . We found that, in parallel, AICD had significantly increased levels in the nucleus of trisomic NPCs (Fig. 6B) . We next examined the potential interaction between AICD and the Ptch1 promoter, by ChIP analysis. Crosslinked chromatin extracts from trisomic and euploid neurospheres, immunoprecipitated with an antibody against AICD, showed the presence of AICD binding to the three regions of the Ptch1 promoter with highest acetylation (Fig. 6C: c-e) . In contrast, in euploid neurospheres, the levels of chromatin extracts immunoprecipitated with AICD were similar to the background (¼1), indicating the absence of AICD binding to the Ptch1 promoter (Fig. 6C) . We treated neurospheres with DAPT, an inhibitor of g-secretase, in order to reduce AICD formation and found that this treatment reduced the binding of AICD to the Ptch1 promoter in trisomic neurospheres (Fig. 6C ). In contrast, the binding of AICD to the Smo promoter was similar in euploid and trisomic neurospheres under basal conditions and after treatment with DAPT (Supplementary Material, Table S1 ). Treatments with DAPT reduced Ptch1 expression in trisomic neurospheres (Fig. 6D) . The same results were obtained with Compound E, another inhibitor of g-secretase (Fig. 6D) . These data provide evidence for a relationship between AICD levels and Ptch1 expression in trisomic neurospheres.
In vivo Ptch1 overexpression in the trisomic brain
In line with recent evidence in P15 pups and adult trisomic mice (27, 39) , we found that neonate (P2) Ts65Dn mice had remarkably fewer proliferating cells (BrdU-positive cells) in the SVZ (euploid: 22260 + 1979, Ts65Dn: 9106 + 2271; P , 0.01) and in the hippocampal dentate gyrus (DG; euploid: 6320 + 2616, Ts65Dn: 2154 + 670; P , 0.05) compared with control mice. As described above, the reduced proliferation rate of trisomic neurospheres (Fig. 1C) was accompanied by a high expression of Ptch1 ( Fig. 2D and E) . * P , 0.05; * * P , 0.01; * * * P , 0.001 (Bonferroni's test after ANOVA).
We next sought to establish whether a similar up-regulation occurred also in the in vivo condition. Analysis of Ptch1 expression in whole brain homogenates derived from neonate Ts65Dn mice showed no difference versus euploid mice (data not shown). However, in view of the small number of precursor cells compared with the number of neurons and glial cells forming the brain, a possible up-regulation of Ptch1 confined to neuronal precursors may be undetectable in whole brain homogenates. Consequently, we analyzed Ptch1 expression by fluorescence immunohistochemistry. Consistently, with the up-regulation of Ptch1 observed in vitro ( Fig. 2D and E; Supplementary Material,  Fig. S1B ), we found that in the SVZ and DG of Ts65Dn mice, Ptch1 had a considerably higher expression compared with that of euploid mice (Fig. 7A -D) . No difference in Ptch1 expression was found in the striatum and prefrontal cortex of Ts65Dn versus euploid mice (Fig. 7A and B) . These data suggest that overexpression of Ptch1 in trisomic mice takes place specifically in proliferating neural precursors.
Recently, we found that human fetuses with DS had remarkably fewer proliferating cells in all germinal zones of the hippocampal region (3, 4) . To establish whether, similarly to the mouse model, fetuses with DS exhibit PTCH1 overexpression, we examined the expression pattern of PTCH1 in the ventricular zone of the hippocampus and parahippocampal gyrus (PHG) (Fig. 8A) . At the examined ages (17 -21 weeks), the ventricular zone of the hippocampus and PHG was formed by several rows of actively dividing cells (4) . Immunohistochemical analysis showed that PTCH1 had a larger expression in the ventricular zone of the hippocampus (+50%) and PHG (+88%) of fetuses with DS (Fig. 8B ), indicating that a defect in PTCH1 expression is present also in neuronal precursor cells of human subjects with DS.
DISCUSSION
We demonstrate here that neuronal precursors from the Ts65Dn mouse exhibit derangement of the Shh pathway due to overexpression of Ptch1, its inhibitory regulator. We found that Ptch1 overexpression was related to increased levels of AICD, a transcription-promoting fragment of the trisomic gene APP. In agreement with the mouse model, we found that PTCH1 was overexpressed also in neuronal precursors of human fetuses with DS. Our results strongly suggest that Ptch1 overexpression is a key determinant of derangement of the Shh pathway and, hence, of the reduced proliferation that characterizes the DS brain.
Cultured trisomic NPCs exhibit the same neurogenesis defects as the in vivo condition
We found here that cultures of NPCs from Ts65Dn mice have a slow proliferation rate due to an elongation of the cell cycle, with a particularly prominent elongation of the G 1 -and G 2 -phases and exhibit an impaired acquisition of a neuronal phenotype. These findings indicate that cultures of NPCs from the Ts65Dn mouse replicate the same proliferation/ differentiation defects observed in vivo (3, 16) , suggesting that the in vitro system faithfully recapitulates the molecular mechanisms that underlie neurogenesis impairment in DS. Our findings are in line with recent studies that have demonstrated proliferation and differentiation impairment in cultures of embryonic NPCs from the Ts1Cje mouse model (40) and from fetuses with DS (41, 42) .
Impairment of the Shh pathway characterizes trisomic NPCs
Accumulating evidence has highlighted the importance of Shh signaling for neuronal precursor proliferation. Shh treatment of cultured neural stem cells derived from the SVZ and hippocampus has been shown to increase proliferation of multipotent neural stem cells (43, 44) . Additionally, while viral delivery of Shh increases proliferation of cells in the hippocampal subgranular zone, conditional knockout of Smo * P , 0.05, * * P , 0.01, * * * P , 0.001 (two-tailed t-test). GR, granule cell layer; H, hilus; I, layer one; II layer two; LW, lateral wall of the lateral ventricle; ML, medial wall of the lateral ventricle; NC, neocortex; ROOF, roof of the lateral ventricle; ST, striatum.
(a membrane protein that mediates the Shh effects) results in a decrease in neural precursor proliferation and neurosphere formation (43, 45) .
Previous research demonstrated that cerebellar granule cell precursors of Ts65Dn mice had a deficit in the Shh-induced mitogenic response versus the euploid counterpart (17) . Due to the very wide brain expression of the Shh pathway, we hypothesized that trisomic NPCs from different neurogenic regions may exhibit a similar Shh response deficit, which would explain the widespread neurogenesis impairment that characterizes the DS brain. We indeed found a deficit in the Shh-induced mitogenic response in NPCs derived from both the SVZ and hippocampus of Ts65Dn mice. The response deficit to Shh in cerebellar granule cells (17) , SVZ and hippocampal precursors confirms our hypothesis that Shh pathway impairment may be a common mechanism that underlies the proliferation deficit of trisomic neuronal precursors.
A recent work in the Ts65Dn mouse demonstrated that neural crest progenitors giving origin to the mandible have a deficient mitotic response to Shh (46) . In addition, recent evidence in human fetuses with DS shows that aberrant lymphatic endothelial cells exhibit an increased Shh expression (47) . These findings suggest that the trisomic condition is characterized by a widespread alteration of the Shh pathway that may involve peripherical tissues.
Ptch1 overexpression underlies impairment of Shh-induced mitogenic response of trisomic NPCs
The molecular and intracellular interactions that transduce the mitogenic response to Shh are not completely understood but are believed to include the nuclear translocation of cytoplasmic Gli1 with increased transcription of MycN, cyclin D, Ptch1 and Gli1 itself (48-50). We found here that genes known to be involved in the Shh pathway exhibited an altered expression in trisomic NPCs. While most of the genes downstream to Shh signaling (including the three Gli proteins and MycN) were down-regulated, there was a large increase in Ptch1 expression.
A defining characteristic of the Shh pathway is the antagonistic relationship between Shh and Ptch1. Activation of the Shh pathway starts with the binding of Shh to its receptor Ptch1, which releases Smo by the Ptch1-dependent inhibition. A recent study has demonstrated, by examining the effects of Ptch1 overexpression in transgenic mice, that a balance between Shh and Ptch1 is necessary for normal brain development (20) . An excess of Ptch1 attenuates the induction of Shh target genes and causes abnormal neural tube patterning. This indicates that Ptch1 overexpression is able to oppose Shh signaling and reveals an important role for Ptch1 in brain development and growth. On the contrary, loss-of-function mutations or transcriptional repression of Ptch1 leads to constitutive activation of Shh signaling pathway and result in an aberrant increase in cell proliferation (51) . We found that either treatment with SAG, an agonist of the Shh pathway that acts downstream to Ptch1 or inhibition of Ptch1 expression by antisense oligonucleotides, can overcome the mitogenic deficit in trisomic NPCs. These results demonstrate that an excess of Ptch1 is the key determinant of the reduced transcription of Shh target gene and proliferation deficits in trisomic NPCs. The notably increased Ptch1 expression in trisomic NPCs explains why Shh levels that were sufficient to activate the pathway in euploid NPCs failed to produce a similar effects in trisomic NPCs. Interestingly, recent studies have demonstrated that by increasing Shh concentration, it is possible to restore the Shh-mitogenic response of trisomic granule cell and neuronal crest precursors (17, 46) . This is in line with our findings, because in the presence of an increased number of Ptch1 molecules (and hence a strong inhibition of the pathway), a corresponding increase in Shh levels is required to activate the pathway in trisomic precursor cells.
In line with data obtained in NPCs from the Ts65Dn mouse model, we found up-regulation of PTCH1 in neuronal precursors of human fetuses with DS. Interestingly, a very recent study (52) identified PTCH1 duplication in a family with microcephaly and mild developmental delay. These patients display many characteristics similar to DS such as hypotonia, developmental delay, flat occipit, broad facies, inner epicanthal folds, brachydactyly, loose joints, heart defects and delayed myelination. According to all this evidence, deregulation of PTCH1 expression may represent a key factor that underlies impairment of neural cell proliferation in individuals with DS and, most likely, also different facets of the somatic DS phenotype.
Mechanisms underlying Ptch1 overexpression in trisomic NPCs
Cleavage of the APP by g-secretase generates the APP intracellular domain (AICD) peptide. Recent evidence shows that AICD is involved in the regulation of gene transcription and that PTCH1 is one of the genes that are regulated by AICD (36, 38, 53) . We found increased levels of AICD in trisomic NPCs, which is in agreement with the overexpression of the trisomic gene APP, and an increased binding of AICD to the Ptch1 promoter. Inhibition of AICD formation reduced the binding of AICD to the Ptch1 promoter and reduced Ptch1 expression. These findings strongly suggest that AICD overexpression underlies Ptch1 up-regulation in trisomic NPCs.
It has been recently shown that, in addition to genetic mutations in PTCH1 (54), epigenetic silencing of PTCH1 promoter by DNA methylation and histone deacetylation contributes to brain tumor formation (32, 55) . We found that while Ptch1 expression was almost unaffected by demethylation (by AZA), it was enhanced by inhibition of deacetylation (by TSA), suggesting that acetylation is a major epigenetic mechanism involved in the regulation of Ptch1 expression in NPCs. The covalent modification of core histones by acetylation leads to a decondensed nucleosomic structure that allows access of transcription factors to the DNA (56) . The finding that in trisomic NPCs, the promoter of Ptch1 was hyper-acethylated suggests that this hyper-acetylation may underlie Ptch1 overexpression. AICD has been reported to form a complex with Fe65 and the histone acetyltransferase Tip60 and cause transcriptional activation by increasing the acetylation status of the chromatin (37, 38) . It may, therefore, be hypothesized that overproduction of AICD in trisomic NPCs may be involved in the hyper-acetylation status of the Ptch1 promoter. Further experiments are needed to clear this issue.
The role of triplicated genes in the neurological phenotype of DS is still poorly understood. Our data suggest that the trisomic gene APP may be a key determinant of impaired neurogenesis in DS, through an AICD-dependent up-regulation of Ptch1 and consequent deregulation of the Shh mitogenic pathway. Interestingly, recent evidence shows that AICD transgenic mice exhibit impaired neurogenesis similarly to trisomic mice (57).
APP is cleaved by different secretases, which may result in functionally distinct outcomes. The amyloidogenic pathway is initiated by b-secretase cleavage of APP to yield the N-terminal soluble APP plus a C-terminal fragment b (CTFb). CTFb can then be processed by g-secretase to generate b-amyloid (Ab) and a free AICD. The current study shows a key role of AICD in neurogenesis defects in DS. Recent evidence suggests that in addition to Ab, AICD may be involved in the pathogenesis of Alzheimer's disease. In agreement with APP triplication and, hence, increased levels of Ab and AICD, most individuals with DS develop Alzheimer's disease after the fourth -fifth decade of life. Compounds that inhibit or modulate g-secretase, the pivotal enzyme that generates both Ab and AICD, may be potential therapeutics for the early neurogenesis impairment and late-occurring neurodegeneration in individuals with DS.
MATERIALS AND METHODS
Ts65Dn mice colony and treatments
Female Ts65Dn mice carrying a partial trisomy of chromosome 16 (10, 58) were obtained from Jackson Laboratories (Bar Harbour, ME, USA) and maintained on the original genetic background by mating them to C57BL/6JEi × C3SnHeSnJ (B6EiC3) F1 males. Animals were karyotyped by real-time qPCR as previously described (59) . The animals had access to water and food ad libitum and lived in a room with a 12:12 h dark/light cycle. Experiments were performed in accordance with the Italian and European Community law for the use of experimental animals and were approved by Bologna University Bioethical Committee. In this study, all efforts were made to minimize animal suffering and to keep to a minimum the number of animals used. On P2 (P0 ¼ day of birth), three euploid and three Ts65Dn mice received a subcutaneous injection (150 mg/g body weight) of BrdU (5-bromo-2-deoxyuridine; Sigma), a marker of proliferating cells in 0.9% NaCl solution and were killed after 2 h to examine cell proliferation.
Human fetuses
The brains of control fetuses (n ¼ 3) and fetuses with DS (n ¼ 3) used in the current study are the same used in previous studies (3, 4 ; see Supplementary Material, Table S2 ).
Histological procedures
P2 mice were decapitated, brains removed and fixed by immersion in Glyo-Fix (Thermo Electron Corp., Waltham, MA, USA) for 48 h and embedded in paraffin. The forebrain was coronally sectioned in 8 mm thick sections that were attached to poly-lysine-coated slides. Fetal brains were fixed by subdural perfusion with Metacarnoy fixative (methyl alcohol: chloroform: acetic acid 6:1:1). After 24 h, the hippocampal region was coronally sectioned into two to three blocks, with a 2 -3 mm thickness. The blocks were post-fixed in formalin (4% buffered formaldehyde) for at least 5 days, embedded in paraffin, according to standard procedures, and sectioned in 5 mm thick coronal sections.
Cell cultures and treatments
Cells were isolated from the SVZ and hippocampus of newborn (P1 -P2) euploid and Ts65Dn mice and neurosphere cultures were obtained as previously reported (60) . Cells were cultured in suspension in Dulbecco's modified Eagle's medium (DMEM)/F12 (1:1) containing B27 supplements (2%), basic fibroblast growth factor (FGF-2, 20 ng/ml), epidermal growth factor (EGF, 20 ng/ml), heparin (5 mg/ml) and antibiotics (penicillin: 100 units/ml; streptomycin: 100 mg/ml). Primary neurospheres were dissociated at days 8 -10 using Accutase (PAA, Pasching, Austria) to derive secondary neurospheres. The sub-culturing protocol consisted of neurosphere passaging every 7 days with whole culture media change (with freshly added FGF-2 and EGF). All experiments were done using neurospheres obtained after three to five passages from the initially prepared cultures. Most (98%) of the cells in neurospheres from the SVZ and hippocampus were positive for nestin, an established marker for neural and glial precursors. Cell cultures were kept in a 5% CO 2 humidified atmosphere at 378C. Treatments were performed for 3 days after cell plating adding fresh reagents every 24 h. The following drugs were used: 3 mg/ml and 6 mg/ml recombinant mouse Sonic Hedgehog Peptide (Shh; Sigma), 250 nM benzo 
Neurosphere diameter measurements
Dissociated neurospheres were plated at a low density (2 × 10 4 cells/ml) and phase contrast images of cells were taken almost every day for 8 days using an Eclipse TE 2000-S inverted microscope (Nikon, Tokyo, Japan). Neurosphere diameters were measured with the NIS-Elements AR software (Nikon).
BrdU immunocytochemistry in neurospheres
For proliferation analysis, dissociated neurospheres were cultured for 3 days, treated with 10 mM BrdU for additional 16 h and harvested on microscope slides by cytospin centrifugation (215g, 5 min, Shandon, Thermo, Dreieich, Germany). Specimens, processed as previously described (24), were incubated with a mouse anti-5-bromo-2-deoxyuridine (BrdU) monoclonal antibody (1:100; Roche Applied Science) and a Cy3-conjugated anti-mouse secondary antibody (1:200; Sigma). Samples were counterstained with Hoechst-33258. Digital images were captured using an Eclipse TE 2000-S microscope and the NIS-Elements AR software (Nikon).
Cell cycle analysis in neurospheres
For determination of total cell cycle length (T C ) and S-phase length (T S ), the BrdU cumulative method was applied (61, 62) . Neurospheres were treated with 10 mm BrdU for 1.5, 3.0, 4.5, 6.0, 24, 48 and 72 h, and fixed and processed for BrdU immunocytochemistry (see above). The labeling index (LI; number of BrdU-positive cells over total cell number) was evaluated in 12 random fields for each sample. LI values obtained at each time point for control and trisomic neurospheres were then plotted as a function of time after BrdU administration as previously described (16, 24) . For evaluation of the number of cells in the G 2 -and M-phases of cell cycle, we used pHH3 immunocytochemistry using an anti-pHH3 antibody (1:200; 06-570 Upstate), and the length of the G 2 -and M-phases of the cell cycle was estimated as previously described (16, 24) . The length of the G 1 -phase was estimated by subtracting from the total length of the cell cycle the length of the other phases.
In vitro differentiation analysis of NPCs
Neurospheres obtained after three passages in vitro were dissociated and plated on cover slips coated with 15 mg/ml poly-L-ornithyine (Sigma). Cells were grown for 2 days and then transferred to a differentiating medium (EGF and FGF free plus 1% foetal bovine serum) for 7 days. Every 3 days, half of the medium was replenished with fresh differentiating medium. Differentiated cells were fixed (see above) and incubated with anti-glial fibrillary acidic protein (1:400; GFAP mouse monoclonal, Sigma) and anti-b-tubulin III (1:100; rabbit polyclonal, Sigma), as primary antibodies, and with anti-mouse FITC-conjugated (1:100; Sigma) and anti-rabbit Cy3-conjugated (1:100; Jackson Laboratories), as secondary antibodies. Samples were counterstained with Hoechst-33258. Cells were counted in five different fields of each cover slip. Number of positive cells for each antibody was referred to the total number of Hoechst-stained nuclei.
Ptch1 quantification in neurospheres
For Ptch1 immunocytochemistry, we used an anti-Ptch1 rat monoclonal antibody (1:50; R&D systems) and, as a secondary antibody, a Cy3-conjugated anti-rat antibody (1:200; Jackson Laboratories). Samples were counterstained with Hoechst-33258. To quantify Ptch1 expression, we used the NIS-Elements AR software (Nikon). For each neurosphere, the perimeter was traced and the mean intensity of the Ptch1 signal was derived by the ratio between the sum of the intensity of positive (bright) pixels and the area of single neurospheres. Approximately 3 neurospheres were analyzed from each slide (three euploid and trisomic mice and two slides for each condition).
BrdU immunohistochemistry
One out of 20 sections from the DG and SVZ of P2 animals was processed for BrdU immunohistochemistry. Sections were processed as previously described (63) and incubated overnight at 48C with a primary antibody anti-BrdU (1:100, Roche Applied Science). Detection was performed with a horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibody (1:200; Jackson Immunoresearch) and DAB kit (Vector Laboratories). Sections were counterstained with hematoxylin. The sampled sections covered the whole rostrocaudal extent of the DG and a region of the SVZ that extended from the rostral pole of the lateral ventricle and stretches for 900 mm in the caudal direction. The total number of BrdUpositive cells was estimated by multiplying the number counted in the series of sampled sections by the inverse of the section sampling fraction (1/20).
Ptch1 immunohistochemistry and quantification in vivo
One out of 12 sections, in P2 animals, and 2 -3 sections of the series of 4 -5 mm thick sections of human fetuses were stained using an anti-Ptch1 rabbit polyclonal antibody (1:50; ab39266 Abcam). Sections were retrieved with citrate buffer (pH 6.0) at 988C for 40 min before incubation with the antibody and processed as previously described (3) . Sections were incubated with Cy3-conjugated anti-rabbit (1:200; Jackson Laboratories) secondary antibody. Image processing and analysis were carried out using the NIS Elements AR software (Nikon). To quantify Ptch1 expression, we normalized the intensity of the signal from the SVZ of mice and hippocampal region of mice and fetuses to that of the corpus callosum and fimbria, respectively.
Western blotting
Total proteins from neurospheres were obtained as previously described (24) . Protein concentration was estimated by the Lowry method (63). Proteins (30 mg) were subjected to electrophoresis on an 8% sodium dodecyl sulphate (SDS)-polyacrylamide gel and transferred to a Hybond ECL nitrocellulose membrane (Amersham Life Science). The following primary antibodies were used: anti-Ptch1 rat monoclonal (1:50; R&D systems) and anti-b-actin (1:2000; Sigma) antibodies. Densitometric analysis of digitized images was performed with Scion Image software (Scion Corporation, Frederick, MD, USA) and intensity for each band was normalized to the intensity of the corresponding b-actin band. For AICD detection, nuclear extracts from neurospheres were prepared as previously described (64) . Proteins (40 mg) were subjected to electrophoresis on a 4 -12% NuPAGE Bis-Tris gel (Invitrogen) and transferred to a nitrocellulose membrane. The membrane was processed for antigen-retrieval as previously described (65) . The blot was incubated with the anti-C-terminal APP rabbit primary antibody (1:8000; A8717 Sigma-Aldrich).
Quantitative real-time PCR and standard RT -PCR Total RNA was isolated from neurosphere cultures with TriReagent (Sigma) according to the manufacturer's instructions. cDNA synthesis was achieved with 1.0 mg of total RNA using the iScript TM cDNA Synthesis Kit according to the manufacturer's instructions. We used the primers (Supplementary Material, Table S3A ) that gave efficiency close to 100%. Realtime PCR was performed using a SYBR Premix Ex Taq kit (Takara, Shiga, Japan) according to the manufacturer's instructions in an iQ5 real-time PCR detection system (Bio-Rad).
Antisense experiments
To silence the expression of Ptch1, experiments were performed by using an antisense oligonucleotide (5 ′ -tcCTCCC AGTTTCCCAGTca-3 ′ ) and, as a control, a sense oligonucleotide (5 ′ -tgACTGGGAAACTGGGAGga-3 ′ ). Both oligonucleotides (Sigma) were phosphorothioated to make them more resistant to the RNAase attack. Dissociated neurospheres were transfected by directly adding either phosphorothioate Ptch1 antisense or sense oligonucleotides into culture medium. Oligonuclotides were daily added (concentration in the culture medium: 10 mM).
Methylcytosine immunoprecipitation (mCIP)
The mCIP method was adapted from previous studies (66, 67) . The DNA was obtained from 4 × 10 6 cells using Blood and Cell DNA culture midi kit (Qiagen) according to the manufacturer's instructions. Immunoprecipitation was performing using 15 mg of sonicated DNA with 5 mg of the mouse anti-methylcytosine monoclonal antibody (Calbiochem NA81) in 600 ml of buffer FB (10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA) at 48C overnight. A fraction of the recovered DNA was used for real-time PCR to determine the amount of the methylated Ptch1 promoter. Primer pairs for real-time PCR analysis were designed to amplify two CpG islands (regions c and e; Fig. 5 ) already described (34) and two non-CpG islands, as control regions (regions a and d; Fig. 5 ) of the mouse Ptch1 promoter. We additionally amplified the CpG-rich region described by Ecke et al. Table S3B ).
Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described (68), using 5 mg of anti-Acetyl-Histone H3 (06-599, Upstate) antibody. A preimmune serum was used as a negative control to determine the baseline of the nonspecific background. Dual crosslinking ChIP, a new variant of ChIP which allows the detection of chromatin components not directly binding to DNA, was performed as previously described (69) using 5 mg of the anti-C-terminal APP antibody (A8717 Sigma-Aldrich) or IgG (sc-2027, Santa Cruz) as a negative control. The immunoprecipitated DNA samples were analyzed by real-time PCR to determine the amount of the histone H3 acetylation of the Ptch1 and Smo promoters and AICD binding to the Ptch1 and Smo promoters (see Supplementary Material, Table S3B ).
Statistical analysis
Results are presented as the mean + standard error (SE) of the mean. Statistical significance was assessed by two-way analysis of variance (ANOVA), followed by Bonferroni's post hoc test or by the two-tailed Student's t-test. A probability level of P , 0.05 was considered to be statistically significant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
